Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03170206
Title Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

lung non-small cell carcinoma

Therapies

Palbociclib

Binimetinib

Binimetinib + Palbociclib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Recruiting Boston Massachusetts 02215 United States Details
Massachusetts General Hospital Not yet recruiting Boston Massachusetts 02215 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field